Neuromuscular Disorders

Featured Article

Understanding ICU-Acquired Neuromuscular Dysfunction: Triggers, Risk Factors, and Treatments

Understanding ICU-Acquired Neuromuscular Dysfunction: Triggers, Risk Factors, and Treatments

ICU-acquired weakness syndromes manifest themselves in a range of ways among patients — as a spectrum of disease rather than in specific form.

Latest

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Investigators assess the diagnostic value of 2 CSF biomarkers to distinguish pediatric acquired demyelinating syndromes from non-acquired demyelinating syndromes.

OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms

OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms

Investigators aim to facilitate early recognition and consideration for patients with Duchenne muscular dystrophy and internalizing psychiatric symptoms.

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

The combination of genetics and exposure to organic solvents in paints and varnishes increases the risk of multiple sclerosis.

Dynamics of Brain Volume Loss Vary With MS Progression

Dynamics of Brain Volume Loss Vary With MS Progression

Brain volume loss has nonlinear dynamics and limited reproducibility as a marker of therapeutic response in multiple sclerosis.

Understanding ICU-Acquired Neuromuscular Dysfunction: Triggers, Risk Factors, and Treatments

Understanding ICU-Acquired Neuromuscular Dysfunction: Triggers, Risk Factors, and Treatments

ICU-acquired weakness syndromes manifest themselves in a range of ways among patients — as a spectrum of disease rather than in specific form.

FDA Lifts Clinical Hold on Trial for Duchenne Muscular Dystrophy Treatment

FDA Lifts Clinical Hold on Trial for Duchenne Muscular Dystrophy Treatment

SGT-001 is a novel adeno-associated viral vector mediated gene transfer that could potentially address the underlying genetic cause of DMD, mutations in the dystrophin gene.

Reduced Disability Progression, Adverse Events Top Considerations When Selecting Multiple Sclerosis Therapy

Reduced Disability Progression, Adverse Events Top Considerations When Selecting Multiple Sclerosis Therapy

A majority of the respondents in both groups identified reduced disability progression as a priority.

Immunotherapy Promising for Slowing Progression of ALS

Immunotherapy Promising for Slowing Progression of ALS

A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis.

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

Sign Up for Free e-newsletters



CME Focus